Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXINASDAQ:MBIONASDAQ:MISTNASDAQ:OPTNNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.12+20.6%$0.15$0.09▼$1.25$5.18M-0.244.61 million shs9.91 million shsMBIOMustang Bio$0.36+2.9%$0.94$0.32▼$8.17$3.71M1.58176,325 shs63,965 shsMISTMilestone Pharmaceuticals$1.59-4.2%$1.67$1.33▼$4.49$84.51M1.77307,891 shs251,681 shsOPTNOptiNose$0.91-2.2%$1.47$0.86▼$2.10$101.95M-0.24832,803 shs23.36 million shsVERUVeru$1.21-8.3%$0.82$0.36▼$1.92$177.12M-0.212.37 million shs2.05 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+24.07%-13.08%-22.52%-22.00%-87.14%MBIOMustang Bio+2.11%-3.64%-61.60%-75.00%-90.81%MISTMilestone Pharmaceuticals-4.79%-2.45%-12.15%+3.25%-57.14%OPTNOptiNose-2.19%-2.45%-38.85%-37.15%-49.72%VERUVeru-8.33%-14.79%+98.39%+181.33%-5.47%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics0.9964 of 5 stars0.05.00.04.62.00.00.0MBIOMustang Bio2.3954 of 5 stars3.55.00.00.03.30.00.0MISTMilestone Pharmaceuticals2.1835 of 5 stars3.45.00.00.00.62.50.0OPTNOptiNose3.6315 of 5 stars3.52.00.04.20.02.50.6VERUVeru1.3269 of 5 stars3.41.00.00.02.91.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics3.00BuyN/AN/AMBIOMustang Bio3.00Buy$17.254,725.17% UpsideMISTMilestone Pharmaceuticals2.75Moderate Buy$10.75576.10% UpsideOPTNOptiNose3.00Buy$4.00341.99% UpsideVERUVeru2.75Moderate Buy$3.33175.48% UpsideCurrent Analyst RatingsLatest MIST, ATXI, OPTN, VERU, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.003/28/2024VERUVeruRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/22/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.003/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.003/5/2024MISTMilestone PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.002/26/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.002/8/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/AMBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AMISTMilestone Pharmaceuticals$1M84.51N/AN/A$0.50 per share3.18OPTNOptiNose$70.99M1.44N/AN/A($0.77) per share-1.18VERUVeru$16.30M10.87N/AN/A$0.22 per share5.50Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)OPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)VERUVeru-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)Latest MIST, ATXI, OPTN, VERU, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 million3/21/2024Q4 2023MISTMilestone Pharmaceuticals-$0.30-$0.32-$0.02-$0.32N/AN/A3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/A3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A1.551.55MBIOMustang BioN/A0.740.74MISTMilestone Pharmaceuticals2.9710.1110.11OPTNOptiNoseN/A0.600.55VERUVeruN/A3.212.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%MBIOMustang Bio9.95%MISTMilestone Pharmaceuticals86.18%OPTNOptiNose85.60%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%MBIOMustang Bio2.10%MISTMilestone Pharmaceuticals10.40%OPTNOptiNose2.20%VERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableMISTMilestone Pharmaceuticals4753.15 million47.62 millionOptionableOPTNOptiNose132112.65 million110.17 millionNot OptionableVERUVeru189146.38 million125.60 millionOptionableMIST, ATXI, OPTN, VERU, and MBIO HeadlinesSourceHeadlineVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11globenewswire.com - April 25 at 8:30 AMNetflix To Stop Sharing Subscriber Data; Stock Dipsmarkets.businessinsider.com - April 19 at 6:13 PMWhat Makes Veru (VERU) a New Buy Stockzacks.com - April 17 at 1:01 PMVeru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimeramericanbankingnews.com - April 16 at 3:26 AMVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimermarketbeat.com - April 15 at 8:29 AMREVEALED: Transport Malta officials at centre of maritime fines corruption racketmaltatoday.com.mt - April 2 at 12:43 AMVeru Announces Date of 2024 Annual Meeting of Shareholdersfinance.yahoo.com - April 1 at 7:43 PMFlag carrier Air Malta ceases operations today, its 50th birthdaymaltatoday.com.mt - March 31 at 6:39 PMVeru Incmorningstar.com - March 29 at 9:35 PMUpdated | Mosta trees vandalised: ERA, police investigatingmaltatoday.com.mt - March 29 at 8:54 AMRaymond James Begins Coverage on Veru (NASDAQ:VERU)marketbeat.com - March 28 at 8:28 AMR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuittherealdeal.com - March 22 at 6:18 PMVeru Reschedules Annual Meeting of Shareholdersglobenewswire.com - March 22 at 4:05 PMWynwood offices targeted in $102M foreclosurebizjournals.com - March 21 at 6:43 PMNaksha Saran plays a bike taxi driver in her next filmmsn.com - March 19 at 4:27 AMPrecise and efficient cutting (sawing) of lightweight core materialsjeccomposites.com - March 18 at 1:24 PMVERU Mar 2024 0.500 putca.finance.yahoo.com - March 16 at 1:30 PMVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Lossglobenewswire.com - March 12 at 8:00 AMVERU Mar 2024 1.500 putfinance.yahoo.com - March 11 at 11:33 PMBrussels is mixed bag of emotions on possible Joseph Muscat returnmaltatoday.com.mt - March 11 at 1:32 PMVERU Jan 2025 17.000 callfinance.yahoo.com - March 9 at 6:52 PMVERU Mar 2024 0.500 callfinance.yahoo.com - March 9 at 1:52 PMVERU Mar 2024 3.000 putfinance.yahoo.com - March 9 at 1:52 PMVERU Mar 2024 2.500 putfinance.yahoo.com - March 1 at 11:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Asian benchmarks mostly climb despite worries about US economyApril 25, 2024 2:14 AMView Stock market today: Asian benchmarks mostly climb despite worries about US economyFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsAll Headlines Company DescriptionsAvenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Milestone PharmaceuticalsNASDAQ:MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.